Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20204729 | 0.89 | POLB (0.37) | HRH3HRH4POLB | |
| SCHEMBL20201744 | 0.86 | PDE9A (0.39) | HRH4POLB | |
| SCHEMBL15219254 | 0.70 | HRH3 (0.45) | HRH3HRH4CACNA1HGBA1CACNA1G | |
| SCHEMBL8489672 | 0.69 | HPGDS (0.48) | HRH3HRH4 | |
| SCHEMBL2514697 | 0.69 | HRH3 (0.47) | HRH3HRH4CACNA1HGBA1CACNA1G | |
| SCHEMBL22751285 | 0.68 | HRH3 (0.33) | HRH3KDM1A | |
| Hydrochloric Acid SCHEMBL22468947 | 0.68 | HPGDS (0.47) | HRH3HRH4 | |
| SCHEMBL1299385 | 0.68 | HRH3 (0.46) | HRH3HRH4CACNA1HGBA1CACNA1G | |
| SCHEMBL20088429 | 0.68 | CACNA1H (0.64) | CACNA1HCACNA1GTDP1 | |
| SCHEMBL5687883 | 0.68 | KDM1A (0.44) | HRH3HRH4GBA1SLC6A4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | ASTEX THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | SGK3, SGK2, GDI2 | HRH3 2042/4885HRH4 1680/4885CACNA1H 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.